Life
U.K. to Review Cost-Effectiveness of New Alzheimer's Treatments
The U.K. government is set to reassess the cost-effectiveness of two Alzheimer's drugs following appeals from manufacturers, which may impact healthcare funding.
Editorial Staff 17 days ago